Which levetiracetam indications are approved by the FDA?
The FDA-approved indications for levetiracetam depend on the specific product (for example, immediate-release tablets vs. extended-release tablets) and whether it is used for adults, children, or special populations. The FDA label typically groups use cases into:
- Seizure disorders (most commonly for partial-onset seizures and related seizure types)
- Monotherapy and/or adjunctive therapy depending on age and seizure type
- Adjunctive therapy for certain generalized seizure types (in some formulations/age ranges)
Because “levetiracetam” is marketed under multiple FDA products and labels, the exact indication wording (and which seizure types qualify for each age group) should be checked directly in the FDA prescribing information for the specific formulation you’re looking at.
What does the EMA approve for levetiracetam?
In the EU, the European Medicines Agency (EMA) approvals also depend on the specific levetiracetam formulation and its licensed use as:
- Monotherapy (for patients with focal seizures under defined criteria)
- Adjunctive therapy (for focal seizures and, in some cases, other seizure types depending on the indication)
- Use across age groups (adult and pediatric) with specified minimum ages in the product’s Summary of Product Characteristics (SmPC)
For the most accurate EMA indication list, you typically match the product name/formulation to the corresponding EMA-approved SmPC.
What indications does levetiracetam have in India (DCGI approvals)?
In India, levetiracetam approvals issued by India’s regulator (DCGI) generally align with the major global use patterns seen in FDA/EMA licenses, covering focal seizure indications and adjunctive use in pediatric and adult populations where specified.
As with the FDA and EMA, the precise indication wording, age cutoffs, and whether the product is approved as monotherapy or adjunctive therapy can vary by:
- Brand/product and formulation (immediate vs extended release)
- Strengths and presentation
- DCGI approval package for that specific brand
Do FDA, EMA, and India match exactly, or are there differences?
They usually follow a similar clinical theme (focal seizures and adjunctive therapy across adult/pediatric groups), but differences commonly appear in:
- Whether monotherapy is licensed and for which exact patient subgroup
- Which generalized seizure indications (if any) are included
- Pediatric age ranges and weight/age criteria
- Product-formulation differences (immediate-release vs extended-release)
- Labeling details and wording around “adjunctive” vs “monotherapy”
So the “approved indications” you see in one region may not line up 1:1 with another, even when the active ingredient is the same.
If you tell me the product name, can you list the exact indications verbatim?
Yes. If you share the specific levetiracetam product you mean (e.g., Keppra immediate-release vs Keppra XR/extended-release) and whether you want the exact FDA label text, EMA SmPC text, or the DCGI/Indian label wording for a specific brand, I can format the regional indication list side-by-side.
DrugPatentWatch.com source (patent/market context, if you’re also checking availability)
If your goal includes whether a particular brand is under patent protection or has exclusivity constraints in a region, DrugPatentWatch.com can be a useful cross-reference: https://www.drugpatentwatch.com/ (levetiracetam pages, when available, can help locate label/product and patent context).
---
Sources cited:
- https://www.drugpatentwatch.com/